{
	"@context": {
		"rdf": "http://www.w3.org/1999/02/22-rdf-syntax-ns#",
		"dct": "http://purl.org/dc/terms/",
		"owl": "http://www.w3.org/2002/07/owl#",
		"xsd": "http://www.w3.org/2001/XMLSchema#",
		"rdfs": "http://www.w3.org/2000/01/rdf-schema#",
		"@vocab": "http://ld.nice.org.uk/ns/bnf#",
		"bnf": "http://ld.nice.org.uk/ns/bnf/",
		"nicebnf": "http://ld.nice.org.uk/ns/bnf#",
		"route": "http://ld.nice.org.uk/ns/bnf/Route#",
		"patientGroup": "http://ld.nice.org.uk/ns/bnf/PatientGroup#",
		"indication": "http://ld.nice.org.uk/ns/bnf/Indication#",
		"sideEffect": "http://ld.nice.org.uk/ns/bnf/SideEffect#",
		"classification": "http://ld.nice.org.uk/ns/bnf/Classification#",
		"isLinkedFrom": {
			"@container": "@set"
		},
		"hasInteraction": {
			"@container": "@set"
		},
		"hasMessage": {
			"@container": "@set"
		},
		"hasInteractionList": {
			"@container": "@set"
		},
		"isInteractionListOf": {
			"@container": "@set"
		}
	},
	"@graph": [
		{
			"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2",
			"@type": "InteractionList",
			"hasInteraction": [
				{
					"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021371",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021371_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tetrabenazine\" outputclass=\"int-heading-drug\">tetrabenazine</ph> and <ph otherprops=\"agomelatine\" outputclass=\"int-drug\">agomelatine</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tetrabenazine  and  agomelatine  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "1",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Agomelatine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021372",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021372_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tetrabenazine\" outputclass=\"int-heading-drug\">tetrabenazine</ph> and <ph otherprops=\"alcohol\" outputclass=\"int-drug\">alcohol</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tetrabenazine  and  alcohol  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "2",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Alcohol</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021373",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021373_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tetrabenazine\" outputclass=\"int-heading-drug\">tetrabenazine</ph> and <ph otherprops=\"alfentanil\" outputclass=\"int-drug\">alfentanil</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tetrabenazine  and  alfentanil  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "3",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Alfentanil</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021374",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021374_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tetrabenazine\" outputclass=\"int-heading-drug\">tetrabenazine</ph> and <ph otherprops=\"alimemazine\" outputclass=\"int-drug\">alimemazine</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tetrabenazine  and  alimemazine  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "4",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Alimemazine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021375",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021375_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tetrabenazine\" outputclass=\"int-heading-drug\">tetrabenazine</ph> and <ph otherprops=\"alprazolam\" outputclass=\"int-drug\">alprazolam</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tetrabenazine  and  alprazolam  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "5",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Alprazolam</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021376",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021376_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"tetrabenazine\" outputclass=\"int-heading-drug\">tetrabenazine</ph> and <ph otherprops=\"amifampridine\" outputclass=\"int-drug\">amifampridine</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  tetrabenazine  and  amifampridine  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						}
					],
					"hasOrder": "6",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Amifampridine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021377",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021377_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"aminophylline\" outputclass=\"int-drug\">Aminophylline</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">cause</ph> <ph outputclass=\"int-parameter\">hypokalaemia (potentially increasing the risk of torsade de pointes) when given with</ph> <ph otherprops=\"tetrabenazine\" outputclass=\"int-heading-drug\">tetrabenazine</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Aminophylline   is predicted to   cause   hypokalaemia (potentially increasing the risk of torsade de pointes) when given with   tetrabenazine .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "7",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Aminophylline</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021378",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021378_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"tetrabenazine\" outputclass=\"int-heading-drug\">tetrabenazine</ph> and <ph otherprops=\"amiodarone\" outputclass=\"int-drug\">amiodarone</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  tetrabenazine  and  amiodarone  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						}
					],
					"hasOrder": "8",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Amiodarone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021379",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021379_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"tetrabenazine\" outputclass=\"int-heading-drug\">tetrabenazine</ph> and <ph otherprops=\"amisulpride\" outputclass=\"int-drug\">amisulpride</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  tetrabenazine  and  amisulpride  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021379_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tetrabenazine\" outputclass=\"int-heading-drug\">tetrabenazine</ph> and <ph otherprops=\"amisulpride\" outputclass=\"int-drug\">amisulpride</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "2",
							"hasTextContent": "Both  tetrabenazine  and  amisulpride  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "9",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Amisulpride</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021380",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021380_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tetrabenazine\" outputclass=\"int-heading-drug\">tetrabenazine</ph> and <ph otherprops=\"amitriptyline\" outputclass=\"int-drug\">amitriptyline</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tetrabenazine  and  amitriptyline  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "10",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Amitriptyline</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021381",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021381_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"amphotericin B\" outputclass=\"int-drug\">Amphotericin B</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">cause</ph> <ph outputclass=\"int-parameter\">hypokalaemia (potentially increasing the risk of torsade de pointes) when given with</ph> <ph otherprops=\"tetrabenazine\" outputclass=\"int-heading-drug\">tetrabenazine</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Amphotericin B   is predicted to   cause   hypokalaemia (potentially increasing the risk of torsade de pointes) when given with   tetrabenazine .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "11",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Amphotericin B</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021382",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021382_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"tetrabenazine\" outputclass=\"int-heading-drug\">tetrabenazine</ph> and <ph otherprops=\"anagrelide\" outputclass=\"int-drug\">anagrelide</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  tetrabenazine  and  anagrelide  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						}
					],
					"hasOrder": "12",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Anagrelide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021383",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021383_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"tetrabenazine\" outputclass=\"int-heading-drug\">tetrabenazine</ph> and <ph otherprops=\"apalutamide\" outputclass=\"int-drug\">apalutamide</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  tetrabenazine  and  apalutamide  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						}
					],
					"hasOrder": "13",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Apalutamide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021384",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021384_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"tetrabenazine\" outputclass=\"int-heading-drug\">tetrabenazine</ph> and <ph otherprops=\"apomorphine\" outputclass=\"int-drug\">apomorphine</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  tetrabenazine  and  apomorphine  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						}
					],
					"hasOrder": "14",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Apomorphine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021385",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021385_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tetrabenazine\" outputclass=\"int-heading-drug\">tetrabenazine</ph> and <ph otherprops=\"apraclonidine\" outputclass=\"int-drug\">apraclonidine</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tetrabenazine  and  apraclonidine  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "15",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Apraclonidine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021386",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021386_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tetrabenazine\" outputclass=\"int-heading-drug\">tetrabenazine</ph> and <ph otherprops=\"aripiprazole\" outputclass=\"int-drug\">aripiprazole</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tetrabenazine  and  aripiprazole  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "16",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Aripiprazole</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021387",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021387_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"tetrabenazine\" outputclass=\"int-heading-drug\">tetrabenazine</ph> and <ph otherprops=\"arsenic trioxide\" outputclass=\"int-drug\">arsenic trioxide</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  tetrabenazine  and  arsenic trioxide  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						}
					],
					"hasOrder": "17",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Arsenic trioxide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021388",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021388_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"tetrabenazine\" outputclass=\"int-heading-drug\">tetrabenazine</ph> and <ph otherprops=\"artemether\" outputclass=\"int-drug\">artemether</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  tetrabenazine  and  artemether  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						}
					],
					"hasOrder": "18",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Artemether</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021389",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021389_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"tetrabenazine\" outputclass=\"int-heading-drug\">tetrabenazine</ph> and <ph otherprops=\"artenimol\" outputclass=\"int-drug\">artenimol</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  tetrabenazine  and  artenimol  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						}
					],
					"hasOrder": "19",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Artenimol</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021390",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021390_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tetrabenazine\" outputclass=\"int-heading-drug\">tetrabenazine</ph> and <ph otherprops=\"articaine\" outputclass=\"int-drug\">articaine</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tetrabenazine  and  articaine  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "20",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Articaine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021391",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021391_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tetrabenazine\" outputclass=\"int-heading-drug\">tetrabenazine</ph> and <ph otherprops=\"asenapine\" outputclass=\"int-drug\">asenapine</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tetrabenazine  and  asenapine  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "21",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Asenapine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021392",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021392_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tetrabenazine\" outputclass=\"int-heading-drug\">tetrabenazine</ph> and <ph otherprops=\"baclofen\" outputclass=\"int-drug\">baclofen</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tetrabenazine  and  baclofen  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "22",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Baclofen</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021393",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021393_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"bambuterol\" outputclass=\"int-drug\">Bambuterol</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">cause</ph> <ph outputclass=\"int-parameter\">hypokalaemia (potentially increasing the risk of torsade de pointes) when given with</ph> <ph otherprops=\"tetrabenazine\" outputclass=\"int-heading-drug\">tetrabenazine</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Bambuterol   is predicted to   cause   hypokalaemia (potentially increasing the risk of torsade de pointes) when given with   tetrabenazine .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "23",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Bambuterol</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021394",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021394_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"beclometasone\" outputclass=\"int-drug\">Beclometasone</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">cause</ph> <ph outputclass=\"int-parameter\">hypokalaemia (potentially increasing the risk of torsade de pointes) when given with</ph> <ph otherprops=\"tetrabenazine\" outputclass=\"int-heading-drug\">tetrabenazine</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Beclometasone   is predicted to   cause   hypokalaemia (potentially increasing the risk of torsade de pointes) when given with   tetrabenazine .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "24",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Beclometasone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021395",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021395_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"tetrabenazine\" outputclass=\"int-heading-drug\">tetrabenazine</ph> and <ph otherprops=\"bedaquiline\" outputclass=\"int-drug\">bedaquiline</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  tetrabenazine  and  bedaquiline  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						}
					],
					"hasOrder": "25",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Bedaquiline</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021396",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021396_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"bendroflumethiazide\" outputclass=\"int-drug\">Bendroflumethiazide</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">cause</ph> <ph outputclass=\"int-parameter\">hypokalaemia (potentially increasing the risk of torsade de pointes) when given with</ph> <ph otherprops=\"tetrabenazine\" outputclass=\"int-heading-drug\">tetrabenazine</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Bendroflumethiazide   is predicted to   cause   hypokalaemia (potentially increasing the risk of torsade de pointes) when given with   tetrabenazine .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "26",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Bendroflumethiazide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021397",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021397_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tetrabenazine\" outputclass=\"int-heading-drug\">tetrabenazine</ph> and <ph otherprops=\"benperidol\" outputclass=\"int-drug\">benperidol</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tetrabenazine  and  benperidol  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "27",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Benperidol</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021398",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021398_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"betamethasone\" outputclass=\"int-drug\">Betamethasone</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">cause</ph> <ph outputclass=\"int-parameter\">hypokalaemia (potentially increasing the risk of torsade de pointes) when given with</ph> <ph otherprops=\"tetrabenazine\" outputclass=\"int-heading-drug\">tetrabenazine</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Betamethasone   is predicted to   cause   hypokalaemia (potentially increasing the risk of torsade de pointes) when given with   tetrabenazine .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "28",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Betamethasone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021399",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021399_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"tetrabenazine\" outputclass=\"int-heading-drug\">tetrabenazine</ph> and <ph otherprops=\"bosutinib\" outputclass=\"int-drug\">bosutinib</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  tetrabenazine  and  bosutinib  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						}
					],
					"hasOrder": "29",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Bosutinib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021400",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021400_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tetrabenazine\" outputclass=\"int-heading-drug\">tetrabenazine</ph> and <ph otherprops=\"brimonidine\" outputclass=\"int-drug\">brimonidine</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tetrabenazine  and  brimonidine  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "30",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Brimonidine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021401",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021401_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tetrabenazine\" outputclass=\"int-heading-drug\">tetrabenazine</ph> and <ph otherprops=\"buclizine\" outputclass=\"int-drug\">buclizine</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tetrabenazine  and  buclizine  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "31",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Buclizine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021402",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021402_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"budesonide\" outputclass=\"int-drug\">Budesonide</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">cause</ph> <ph outputclass=\"int-parameter\">hypokalaemia (potentially increasing the risk of torsade de pointes) when given with</ph> <ph otherprops=\"tetrabenazine\" outputclass=\"int-heading-drug\">tetrabenazine</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Budesonide   is predicted to   cause   hypokalaemia (potentially increasing the risk of torsade de pointes) when given with   tetrabenazine .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "32",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Budesonide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021403",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021403_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"bumetanide\" outputclass=\"int-drug\">Bumetanide</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">cause</ph> <ph outputclass=\"int-parameter\">hypokalaemia (potentially increasing the risk of torsade de pointes) when given with</ph> <ph otherprops=\"tetrabenazine\" outputclass=\"int-heading-drug\">tetrabenazine</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Bumetanide   is predicted to   cause   hypokalaemia (potentially increasing the risk of torsade de pointes) when given with   tetrabenazine .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "33",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Bumetanide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021404",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021404_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tetrabenazine\" outputclass=\"int-heading-drug\">tetrabenazine</ph> and <ph otherprops=\"bupivacaine\" outputclass=\"int-drug\">bupivacaine</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tetrabenazine  and  bupivacaine  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "34",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Bupivacaine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021405",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021405_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tetrabenazine\" outputclass=\"int-heading-drug\">tetrabenazine</ph> and <ph otherprops=\"buprenorphine\" outputclass=\"int-drug\">buprenorphine</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tetrabenazine  and  buprenorphine  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "35",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Buprenorphine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021406",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021406_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"bupropion\" outputclass=\"int-drug\">Bupropion</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to the active metabolite of</ph> <ph otherprops=\"tetrabenazine\" outputclass=\"int-heading-drug\">tetrabenazine</ph>. <ph outputclass=\"int-action\">Manufacturer advises caution</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Bupropion   is predicted to   increase   the exposure to the active metabolite of   tetrabenazine .  Manufacturer advises caution .    \n\n"
						}
					],
					"hasOrder": "36",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Bupropion</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021407",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021407_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"tetrabenazine\" outputclass=\"int-heading-drug\">tetrabenazine</ph> and <ph otherprops=\"cabozantinib\" outputclass=\"int-drug\">cabozantinib</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  tetrabenazine  and  cabozantinib  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						}
					],
					"hasOrder": "37",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Cabozantinib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021408",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021408_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tetrabenazine\" outputclass=\"int-heading-drug\">tetrabenazine</ph> and <ph otherprops=\"cannabidiol\" outputclass=\"int-drug\">cannabidiol</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tetrabenazine  and  cannabidiol  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "38",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Cannabidiol</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021409",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021409_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tetrabenazine\" outputclass=\"int-heading-drug\">tetrabenazine</ph> and <ph otherprops=\"cariprazine\" outputclass=\"int-drug\">cariprazine</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tetrabenazine  and  cariprazine  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "39",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Cariprazine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021410",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021410_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tetrabenazine\" outputclass=\"int-heading-drug\">tetrabenazine</ph> and <ph otherprops=\"cenobamate\" outputclass=\"int-drug\">cenobamate</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tetrabenazine  and  cenobamate  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "40",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Cenobamate</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021411",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021411_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"tetrabenazine\" outputclass=\"int-heading-drug\">tetrabenazine</ph> and <ph otherprops=\"ceritinib\" outputclass=\"int-drug\">ceritinib</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  tetrabenazine  and  ceritinib  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						}
					],
					"hasOrder": "41",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Ceritinib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021412",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021412_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tetrabenazine\" outputclass=\"int-heading-drug\">tetrabenazine</ph> and <ph otherprops=\"chloral hydrate\" outputclass=\"int-drug\">chloral hydrate</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tetrabenazine  and  chloral hydrate  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "42",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Chloral hydrate</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021413",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021413_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tetrabenazine\" outputclass=\"int-heading-drug\">tetrabenazine</ph> and <ph otherprops=\"chlordiazepoxide\" outputclass=\"int-drug\">chlordiazepoxide</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tetrabenazine  and  chlordiazepoxide  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "43",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Chlordiazepoxide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021414",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021414_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tetrabenazine\" outputclass=\"int-heading-drug\">tetrabenazine</ph> and <ph otherprops=\"chloroprocaine\" outputclass=\"int-drug\">chloroprocaine</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tetrabenazine  and  chloroprocaine  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "44",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Chloroprocaine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021415",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021415_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"chlorothiazide\" outputclass=\"int-drug\">Chlorothiazide</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">cause</ph> <ph outputclass=\"int-parameter\">hypokalaemia (potentially increasing the risk of torsade de pointes) when given with</ph> <ph otherprops=\"tetrabenazine\" outputclass=\"int-heading-drug\">tetrabenazine</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Chlorothiazide   is predicted to   cause   hypokalaemia (potentially increasing the risk of torsade de pointes) when given with   tetrabenazine .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "45",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Chlorothiazide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021416",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021416_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tetrabenazine\" outputclass=\"int-heading-drug\">tetrabenazine</ph> and <ph otherprops=\"chlorphenamine\" outputclass=\"int-drug\">chlorphenamine</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tetrabenazine  and  chlorphenamine  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "46",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Chlorphenamine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021417",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021417_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"tetrabenazine\" outputclass=\"int-heading-drug\">tetrabenazine</ph> and <ph otherprops=\"chlorpromazine\" outputclass=\"int-drug\">chlorpromazine</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  tetrabenazine  and  chlorpromazine  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021417_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tetrabenazine\" outputclass=\"int-heading-drug\">tetrabenazine</ph> and <ph otherprops=\"chlorpromazine\" outputclass=\"int-drug\">chlorpromazine</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "2",
							"hasTextContent": "Both  tetrabenazine  and  chlorpromazine  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "47",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Chlorpromazine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021418",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021418_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"chlortalidone\" outputclass=\"int-drug\">Chlortalidone</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">cause</ph> <ph outputclass=\"int-parameter\">hypokalaemia (potentially increasing the risk of torsade de pointes) when given with</ph> <ph otherprops=\"tetrabenazine\" outputclass=\"int-heading-drug\">tetrabenazine</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Chlortalidone   is predicted to   cause   hypokalaemia (potentially increasing the risk of torsade de pointes) when given with   tetrabenazine .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "48",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Chlortalidone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021419",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021419_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"cinacalcet\" outputclass=\"int-drug\">Cinacalcet</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to the active metabolite of</ph> <ph otherprops=\"tetrabenazine\" outputclass=\"int-heading-drug\">tetrabenazine</ph>. <ph outputclass=\"int-action\">Manufacturer advises caution</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Cinacalcet   is predicted to   increase   the exposure to the active metabolite of   tetrabenazine .  Manufacturer advises caution .    \n\n"
						}
					],
					"hasOrder": "49",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Cinacalcet</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021420",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021420_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tetrabenazine\" outputclass=\"int-heading-drug\">tetrabenazine</ph> and <ph otherprops=\"cinnarizine\" outputclass=\"int-drug\">cinnarizine</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tetrabenazine  and  cinnarizine  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "50",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Cinnarizine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021421",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021421_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"tetrabenazine\" outputclass=\"int-heading-drug\">tetrabenazine</ph> and <ph otherprops=\"citalopram\" outputclass=\"int-drug\">citalopram</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  tetrabenazine  and  citalopram  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						}
					],
					"hasOrder": "51",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Citalopram</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021422",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021422_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"tetrabenazine\" outputclass=\"int-heading-drug\">tetrabenazine</ph> and <ph otherprops=\"clarithromycin\" outputclass=\"int-drug\">clarithromycin</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  tetrabenazine  and  clarithromycin  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						}
					],
					"hasOrder": "52",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Clarithromycin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021423",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021423_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tetrabenazine\" outputclass=\"int-heading-drug\">tetrabenazine</ph> and <ph otherprops=\"clemastine\" outputclass=\"int-drug\">clemastine</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tetrabenazine  and  clemastine  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "53",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Clemastine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021424",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021424_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tetrabenazine\" outputclass=\"int-heading-drug\">tetrabenazine</ph> and <ph otherprops=\"clobazam\" outputclass=\"int-drug\">clobazam</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tetrabenazine  and  clobazam  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "54",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Clobazam</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021425",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021425_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tetrabenazine\" outputclass=\"int-heading-drug\">tetrabenazine</ph> and <ph otherprops=\"clomethiazole\" outputclass=\"int-drug\">clomethiazole</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tetrabenazine  and  clomethiazole  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "55",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Clomethiazole</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021426",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021426_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"tetrabenazine\" outputclass=\"int-heading-drug\">tetrabenazine</ph> and <ph otherprops=\"clomipramine\" outputclass=\"int-drug\">clomipramine</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  tetrabenazine  and  clomipramine  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021426_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tetrabenazine\" outputclass=\"int-heading-drug\">tetrabenazine</ph> and <ph otherprops=\"clomipramine\" outputclass=\"int-drug\">clomipramine</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "2",
							"hasTextContent": "Both  tetrabenazine  and  clomipramine  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "56",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Clomipramine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021427",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021427_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tetrabenazine\" outputclass=\"int-heading-drug\">tetrabenazine</ph> and <ph otherprops=\"clonazepam\" outputclass=\"int-drug\">clonazepam</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tetrabenazine  and  clonazepam  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "57",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Clonazepam</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021428",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021428_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tetrabenazine\" outputclass=\"int-heading-drug\">tetrabenazine</ph> and <ph otherprops=\"clonidine\" outputclass=\"int-drug\">clonidine</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tetrabenazine  and  clonidine  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "58",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Clonidine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021429",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021429_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tetrabenazine\" outputclass=\"int-heading-drug\">tetrabenazine</ph> and <ph otherprops=\"clozapine\" outputclass=\"int-drug\">clozapine</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tetrabenazine  and  clozapine  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "59",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Clozapine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021430",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021430_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tetrabenazine\" outputclass=\"int-heading-drug\">tetrabenazine</ph> and <ph otherprops=\"codeine\" outputclass=\"int-drug\">codeine</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tetrabenazine  and  codeine  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "60",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Codeine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021431",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021431_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"tetrabenazine\" outputclass=\"int-heading-drug\">tetrabenazine</ph> and <ph otherprops=\"crizotinib\" outputclass=\"int-drug\">crizotinib</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  tetrabenazine  and  crizotinib  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						}
					],
					"hasOrder": "61",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Crizotinib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021432",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021432_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tetrabenazine\" outputclass=\"int-heading-drug\">tetrabenazine</ph> and <ph otherprops=\"cyclizine\" outputclass=\"int-drug\">cyclizine</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tetrabenazine  and  cyclizine  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "62",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Cyclizine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021433",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021433_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tetrabenazine\" outputclass=\"int-heading-drug\">tetrabenazine</ph> and <ph otherprops=\"cyproheptadine\" outputclass=\"int-drug\">cyproheptadine</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tetrabenazine  and  cyproheptadine  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "63",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Cyproheptadine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021434",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021434_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"tetrabenazine\" outputclass=\"int-heading-drug\">tetrabenazine</ph> and <ph otherprops=\"dasatinib\" outputclass=\"int-drug\">dasatinib</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  tetrabenazine  and  dasatinib  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						}
					],
					"hasOrder": "64",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Dasatinib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021435",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021435_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"deflazacort\" outputclass=\"int-drug\">Deflazacort</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">cause</ph> <ph outputclass=\"int-parameter\">hypokalaemia (potentially increasing the risk of torsade de pointes) when given with</ph> <ph otherprops=\"tetrabenazine\" outputclass=\"int-heading-drug\">tetrabenazine</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Deflazacort   is predicted to   cause   hypokalaemia (potentially increasing the risk of torsade de pointes) when given with   tetrabenazine .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "65",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Deflazacort</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021436",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021436_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"tetrabenazine\" outputclass=\"int-heading-drug\">tetrabenazine</ph> and <ph otherprops=\"delamanid\" outputclass=\"int-drug\">delamanid</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  tetrabenazine  and  delamanid  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						}
					],
					"hasOrder": "66",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Delamanid</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021437",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021437_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"tetrabenazine\" outputclass=\"int-heading-drug\">tetrabenazine</ph> and <ph otherprops=\"desflurane\" outputclass=\"int-drug\">desflurane</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  tetrabenazine  and  desflurane  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021437_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tetrabenazine\" outputclass=\"int-heading-drug\">tetrabenazine</ph> and <ph otherprops=\"desflurane\" outputclass=\"int-drug\">desflurane</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "2",
							"hasTextContent": "Both  tetrabenazine  and  desflurane  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "67",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Desflurane</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021438",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021438_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"dexamethasone\" outputclass=\"int-drug\">Dexamethasone</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">cause</ph> <ph outputclass=\"int-parameter\">hypokalaemia (potentially increasing the risk of torsade de pointes) when given with</ph> <ph otherprops=\"tetrabenazine\" outputclass=\"int-heading-drug\">tetrabenazine</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Dexamethasone   is predicted to   cause   hypokalaemia (potentially increasing the risk of torsade de pointes) when given with   tetrabenazine .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "68",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Dexamethasone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021439",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021439_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tetrabenazine\" outputclass=\"int-heading-drug\">tetrabenazine</ph> and <ph otherprops=\"dexmedetomidine\" outputclass=\"int-drug\">dexmedetomidine</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tetrabenazine  and  dexmedetomidine  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "69",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Dexmedetomidine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021440",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021440_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tetrabenazine\" outputclass=\"int-heading-drug\">tetrabenazine</ph> and <ph otherprops=\"diamorphine\" outputclass=\"int-drug\">diamorphine</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tetrabenazine  and  diamorphine  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "70",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Diamorphine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021441",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021441_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tetrabenazine\" outputclass=\"int-heading-drug\">tetrabenazine</ph> and <ph otherprops=\"diazepam\" outputclass=\"int-drug\">diazepam</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tetrabenazine  and  diazepam  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "71",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Diazepam</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021442",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021442_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tetrabenazine\" outputclass=\"int-heading-drug\">tetrabenazine</ph> and <ph otherprops=\"dihydrocodeine\" outputclass=\"int-drug\">dihydrocodeine</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tetrabenazine  and  dihydrocodeine  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "72",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Dihydrocodeine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021443",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021443_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tetrabenazine\" outputclass=\"int-heading-drug\">tetrabenazine</ph> and <ph otherprops=\"dipipanone\" outputclass=\"int-drug\">dipipanone</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tetrabenazine  and  dipipanone  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "73",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Dipipanone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021444",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021444_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"tetrabenazine\" outputclass=\"int-heading-drug\">tetrabenazine</ph> and <ph otherprops=\"disopyramide\" outputclass=\"int-drug\">disopyramide</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  tetrabenazine  and  disopyramide  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						}
					],
					"hasOrder": "74",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Disopyramide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021445",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021445_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"domperidone\" outputclass=\"int-drug\">Domperidone</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the risk of QT-prolongation when given with</ph> <ph otherprops=\"tetrabenazine\" outputclass=\"int-heading-drug\">tetrabenazine</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Domperidone   increases   the risk of QT-prolongation when given with   tetrabenazine .  Manufacturer advises avoid .    \n\n"
						}
					],
					"hasOrder": "75",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Domperidone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021446",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021446_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tetrabenazine\" outputclass=\"int-heading-drug\">tetrabenazine</ph> and <ph otherprops=\"dosulepin\" outputclass=\"int-drug\">dosulepin</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tetrabenazine  and  dosulepin  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "76",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Dosulepin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021447",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021447_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tetrabenazine\" outputclass=\"int-heading-drug\">tetrabenazine</ph> and <ph otherprops=\"doxepin\" outputclass=\"int-drug\">doxepin</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tetrabenazine  and  doxepin  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "77",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Doxepin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021448",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021448_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tetrabenazine\" outputclass=\"int-heading-drug\">tetrabenazine</ph> and <ph otherprops=\"dronabinol\" outputclass=\"int-drug\">dronabinol</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tetrabenazine  and  dronabinol  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "78",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Dronabinol</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021449",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021449_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"tetrabenazine\" outputclass=\"int-heading-drug\">tetrabenazine</ph> and <ph otherprops=\"dronedarone\" outputclass=\"int-drug\">dronedarone</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  tetrabenazine  and  dronedarone  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						}
					],
					"hasOrder": "79",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Dronedarone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021450",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021450_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"tetrabenazine\" outputclass=\"int-heading-drug\">tetrabenazine</ph> and <ph otherprops=\"droperidol\" outputclass=\"int-drug\">droperidol</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  tetrabenazine  and  droperidol  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021450_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tetrabenazine\" outputclass=\"int-heading-drug\">tetrabenazine</ph> and <ph otherprops=\"droperidol\" outputclass=\"int-drug\">droperidol</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "2",
							"hasTextContent": "Both  tetrabenazine  and  droperidol  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "80",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Droperidol</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021451",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021451_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"tetrabenazine\" outputclass=\"int-heading-drug\">tetrabenazine</ph> and <ph otherprops=\"efavirenz\" outputclass=\"int-drug\">efavirenz</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  tetrabenazine  and  efavirenz  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						}
					],
					"hasOrder": "81",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Efavirenz</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021452",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021452_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"tetrabenazine\" outputclass=\"int-heading-drug\">tetrabenazine</ph> and <ph otherprops=\"encorafenib\" outputclass=\"int-drug\">encorafenib</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  tetrabenazine  and  encorafenib  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						}
					],
					"hasOrder": "82",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Encorafenib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021453",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021453_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"tetrabenazine\" outputclass=\"int-heading-drug\">tetrabenazine</ph> and <ph otherprops=\"entrectinib\" outputclass=\"int-drug\">entrectinib</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  tetrabenazine  and  entrectinib  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						}
					],
					"hasOrder": "83",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Entrectinib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021454",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021454_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"tetrabenazine\" outputclass=\"int-heading-drug\">tetrabenazine</ph> and <ph otherprops=\"eribulin\" outputclass=\"int-drug\">eribulin</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  tetrabenazine  and  eribulin  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						}
					],
					"hasOrder": "84",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Eribulin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021455",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021455_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"tetrabenazine\" outputclass=\"int-heading-drug\">tetrabenazine</ph> and <ph otherprops=\"erythromycin\" outputclass=\"int-drug\">erythromycin</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  tetrabenazine  and  erythromycin  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						}
					],
					"hasOrder": "85",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Erythromycin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021456",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021456_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"tetrabenazine\" outputclass=\"int-heading-drug\">tetrabenazine</ph> and <ph otherprops=\"escitalopram\" outputclass=\"int-drug\">escitalopram</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  tetrabenazine  and  escitalopram  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						}
					],
					"hasOrder": "86",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Escitalopram</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021457",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021457_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tetrabenazine\" outputclass=\"int-heading-drug\">tetrabenazine</ph> and <ph otherprops=\"esketamine\" outputclass=\"int-drug\">esketamine</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tetrabenazine  and  esketamine  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "87",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Esketamine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021458",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021458_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tetrabenazine\" outputclass=\"int-heading-drug\">tetrabenazine</ph> and <ph otherprops=\"etomidate\" outputclass=\"int-drug\">etomidate</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tetrabenazine  and  etomidate  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "88",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Etomidate</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021459",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021459_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tetrabenazine\" outputclass=\"int-heading-drug\">tetrabenazine</ph> and <ph otherprops=\"fentanyl\" outputclass=\"int-drug\">fentanyl</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tetrabenazine  and  fentanyl  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "89",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Fentanyl</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021460",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021460_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"fingolimod\" outputclass=\"int-drug\">Fingolimod</ph> <ph outputclass=\"int-effectQualifier\">might</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of QT-prolongation when given with</ph> <ph otherprops=\"tetrabenazine\" outputclass=\"int-heading-drug\">tetrabenazine</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Fingolimod   might   increase   the risk of QT-prolongation when given with   tetrabenazine .  Manufacturer advises avoid .    \n\n"
						}
					],
					"hasOrder": "90",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Fingolimod</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021461",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021461_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"tetrabenazine\" outputclass=\"int-heading-drug\">tetrabenazine</ph> and <ph otherprops=\"flecainide\" outputclass=\"int-drug\">flecainide</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  tetrabenazine  and  flecainide  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						}
					],
					"hasOrder": "91",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Flecainide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021462",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021462_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"tetrabenazine\" outputclass=\"int-heading-drug\">tetrabenazine</ph> and <ph otherprops=\"fluconazole\" outputclass=\"int-drug\">fluconazole</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  tetrabenazine  and  fluconazole  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						}
					],
					"hasOrder": "92",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Fluconazole</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021463",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021463_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"fludrocortisone\" outputclass=\"int-drug\">Fludrocortisone</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">cause</ph> <ph outputclass=\"int-parameter\">hypokalaemia (potentially increasing the risk of torsade de pointes) when given with</ph> <ph otherprops=\"tetrabenazine\" outputclass=\"int-heading-drug\">tetrabenazine</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Fludrocortisone   is predicted to   cause   hypokalaemia (potentially increasing the risk of torsade de pointes) when given with   tetrabenazine .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "93",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Fludrocortisone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021464",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021464_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"fluoxetine\" outputclass=\"int-drug\">Fluoxetine</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to the active metabolite of</ph> <ph otherprops=\"tetrabenazine\" outputclass=\"int-heading-drug\">tetrabenazine</ph>. <ph outputclass=\"int-action\">Manufacturer advises caution</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Fluoxetine   is predicted to   increase   the exposure to the active metabolite of   tetrabenazine .  Manufacturer advises caution .    \n\n"
						}
					],
					"hasOrder": "94",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Fluoxetine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021465",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021465_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tetrabenazine\" outputclass=\"int-heading-drug\">tetrabenazine</ph> and <ph otherprops=\"flupentixol\" outputclass=\"int-drug\">flupentixol</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tetrabenazine  and  flupentixol  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "95",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Flupentixol</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021466",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021466_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tetrabenazine\" outputclass=\"int-heading-drug\">tetrabenazine</ph> and <ph otherprops=\"flurazepam\" outputclass=\"int-drug\">flurazepam</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tetrabenazine  and  flurazepam  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "96",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Flurazepam</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021467",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021467_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"formoterol\" outputclass=\"int-drug\">Formoterol</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">cause</ph> <ph outputclass=\"int-parameter\">hypokalaemia (potentially increasing the risk of torsade de pointes) when given with</ph> <ph otherprops=\"tetrabenazine\" outputclass=\"int-heading-drug\">tetrabenazine</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Formoterol   is predicted to   cause   hypokalaemia (potentially increasing the risk of torsade de pointes) when given with   tetrabenazine .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "97",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Formoterol</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021468",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021468_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"furosemide\" outputclass=\"int-drug\">Furosemide</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">cause</ph> <ph outputclass=\"int-parameter\">hypokalaemia (potentially increasing the risk of torsade de pointes) when given with</ph> <ph otherprops=\"tetrabenazine\" outputclass=\"int-heading-drug\">tetrabenazine</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Furosemide   is predicted to   cause   hypokalaemia (potentially increasing the risk of torsade de pointes) when given with   tetrabenazine .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "98",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Furosemide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021469",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021469_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tetrabenazine\" outputclass=\"int-heading-drug\">tetrabenazine</ph> and <ph otherprops=\"gabapentin\" outputclass=\"int-drug\">gabapentin</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tetrabenazine  and  gabapentin  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "99",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Gabapentin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021470",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021470_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"tetrabenazine\" outputclass=\"int-heading-drug\">tetrabenazine</ph> and <ph otherprops=\"glasdegib\" outputclass=\"int-drug\">glasdegib</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  tetrabenazine  and  glasdegib  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						}
					],
					"hasOrder": "100",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Glasdegib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021471",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021471_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"granisetron\" outputclass=\"int-drug\">Granisetron</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of QT-prolongation when given with</ph> <ph otherprops=\"tetrabenazine\" outputclass=\"int-heading-drug\">tetrabenazine</ph>. <ph outputclass=\"int-action\">Manufacturer advises caution</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Granisetron   is predicted to   increase   the risk of QT-prolongation when given with   tetrabenazine .  Manufacturer advises caution .    \n\n"
						}
					],
					"hasOrder": "101",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Granisetron</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021472",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021472_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tetrabenazine\" outputclass=\"int-heading-drug\">tetrabenazine</ph> and <ph otherprops=\"guanfacine\" outputclass=\"int-drug\">guanfacine</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tetrabenazine  and  guanfacine  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "102",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Guanfacine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021473",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021473_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"tetrabenazine\" outputclass=\"int-heading-drug\">tetrabenazine</ph> and <ph otherprops=\"haloperidol\" outputclass=\"int-drug\">haloperidol</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  tetrabenazine  and  haloperidol  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021473_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tetrabenazine\" outputclass=\"int-heading-drug\">tetrabenazine</ph> and <ph otherprops=\"haloperidol\" outputclass=\"int-drug\">haloperidol</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "2",
							"hasTextContent": "Both  tetrabenazine  and  haloperidol  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "103",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Haloperidol</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021474",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021474_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"hydrochlorothiazide\" outputclass=\"int-drug\">Hydrochlorothiazide</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">cause</ph> <ph outputclass=\"int-parameter\">hypokalaemia (potentially increasing the risk of torsade de pointes) when given with</ph> <ph otherprops=\"tetrabenazine\" outputclass=\"int-heading-drug\">tetrabenazine</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Hydrochlorothiazide   is predicted to   cause   hypokalaemia (potentially increasing the risk of torsade de pointes) when given with   tetrabenazine .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "104",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Hydrochlorothiazide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021475",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021475_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"hydrocortisone\" outputclass=\"int-drug\">Hydrocortisone</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">cause</ph> <ph outputclass=\"int-parameter\">hypokalaemia (potentially increasing the risk of torsade de pointes) when given with</ph> <ph otherprops=\"tetrabenazine\" outputclass=\"int-heading-drug\">tetrabenazine</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Hydrocortisone   is predicted to   cause   hypokalaemia (potentially increasing the risk of torsade de pointes) when given with   tetrabenazine .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "105",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Hydrocortisone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021476",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021476_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"hydroflumethiazide\" outputclass=\"int-drug\">Hydroflumethiazide</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">cause</ph> <ph outputclass=\"int-parameter\">hypokalaemia (potentially increasing the risk of torsade de pointes) when given with</ph> <ph otherprops=\"tetrabenazine\" outputclass=\"int-heading-drug\">tetrabenazine</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Hydroflumethiazide   is predicted to   cause   hypokalaemia (potentially increasing the risk of torsade de pointes) when given with   tetrabenazine .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "106",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Hydroflumethiazide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021477",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021477_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tetrabenazine\" outputclass=\"int-heading-drug\">tetrabenazine</ph> and <ph otherprops=\"hydromorphone\" outputclass=\"int-drug\">hydromorphone</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tetrabenazine  and  hydromorphone  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "107",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Hydromorphone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021478",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021478_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"tetrabenazine\" outputclass=\"int-heading-drug\">tetrabenazine</ph> and <ph otherprops=\"hydroxychloroquine\" outputclass=\"int-drug\">hydroxychloroquine</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  tetrabenazine  and  hydroxychloroquine  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						}
					],
					"hasOrder": "108",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Hydroxychloroquine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021479",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021479_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"tetrabenazine\" outputclass=\"int-heading-drug\">tetrabenazine</ph> and <ph otherprops=\"hydroxyzine\" outputclass=\"int-drug\">hydroxyzine</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  tetrabenazine  and  hydroxyzine  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021479_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tetrabenazine\" outputclass=\"int-heading-drug\">tetrabenazine</ph> and <ph otherprops=\"hydroxyzine\" outputclass=\"int-drug\">hydroxyzine</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "2",
							"hasTextContent": "Both  tetrabenazine  and  hydroxyzine  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "109",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Hydroxyzine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021480",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021480_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tetrabenazine\" outputclass=\"int-heading-drug\">tetrabenazine</ph> and <ph otherprops=\"imipramine\" outputclass=\"int-drug\">imipramine</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tetrabenazine  and  imipramine  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "110",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Imipramine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021481",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021481_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"indacaterol\" outputclass=\"int-drug\">Indacaterol</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">cause</ph> <ph outputclass=\"int-parameter\">hypokalaemia (potentially increasing the risk of torsade de pointes) when given with</ph> <ph otherprops=\"tetrabenazine\" outputclass=\"int-heading-drug\">tetrabenazine</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Indacaterol   is predicted to   cause   hypokalaemia (potentially increasing the risk of torsade de pointes) when given with   tetrabenazine .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "111",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Indacaterol</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021482",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021482_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"indapamide\" outputclass=\"int-drug\">Indapamide</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">cause</ph> <ph outputclass=\"int-parameter\">hypokalaemia (potentially increasing the risk of torsade de pointes) when given with</ph> <ph otherprops=\"tetrabenazine\" outputclass=\"int-heading-drug\">tetrabenazine</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Indapamide   is predicted to   cause   hypokalaemia (potentially increasing the risk of torsade de pointes) when given with   tetrabenazine .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "112",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Indapamide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021483",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021483_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"tetrabenazine\" outputclass=\"int-heading-drug\">tetrabenazine</ph> and <ph otherprops=\"inotuzumab ozogamicin\" outputclass=\"int-drug\">inotuzumab ozogamicin</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  tetrabenazine  and  inotuzumab ozogamicin  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						}
					],
					"hasOrder": "113",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Inotuzumab ozogamicin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021484",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021484_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"tetrabenazine\" outputclass=\"int-heading-drug\">Tetrabenazine</ph> <ph outputclass=\"int-effectQualifier\">potentially</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the risk of CNS excitation and hypertension when given with</ph> <ph otherprops=\"isocarboxazid\" outputclass=\"int-drug\">isocarboxazid</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid and for 14 days after stopping the MAOI</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Tetrabenazine   potentially   increases   the risk of CNS excitation and hypertension when given with   isocarboxazid .  Manufacturer advises avoid and for 14 days after stopping the MAOI .    \n\n"
						}
					],
					"hasOrder": "114",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Isocarboxazid</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021485",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021485_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"tetrabenazine\" outputclass=\"int-heading-drug\">tetrabenazine</ph> and <ph otherprops=\"isoflurane\" outputclass=\"int-drug\">isoflurane</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  tetrabenazine  and  isoflurane  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021485_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tetrabenazine\" outputclass=\"int-heading-drug\">tetrabenazine</ph> and <ph otherprops=\"isoflurane\" outputclass=\"int-drug\">isoflurane</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "2",
							"hasTextContent": "Both  tetrabenazine  and  isoflurane  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "115",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Isoflurane</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021486",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021486_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"ivabradine\" outputclass=\"int-drug\">Ivabradine</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of torsade de pointes when given with</ph> <ph otherprops=\"tetrabenazine\" outputclass=\"int-heading-drug\">tetrabenazine</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Ivabradine   is predicted to   increase   the risk of torsade de pointes when given with   tetrabenazine .  Manufacturer advises avoid .    \n\n"
						}
					],
					"hasOrder": "116",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Ivabradine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021487",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021487_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tetrabenazine\" outputclass=\"int-heading-drug\">tetrabenazine</ph> and <ph otherprops=\"ketamine\" outputclass=\"int-drug\">ketamine</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tetrabenazine  and  ketamine  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "117",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Ketamine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021488",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021488_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tetrabenazine\" outputclass=\"int-heading-drug\">tetrabenazine</ph> and <ph otherprops=\"ketotifen\" outputclass=\"int-drug\">ketotifen</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tetrabenazine  and  ketotifen  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "118",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Ketotifen</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021489",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021489_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tetrabenazine\" outputclass=\"int-heading-drug\">tetrabenazine</ph> and <ph otherprops=\"lamotrigine\" outputclass=\"int-drug\">lamotrigine</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tetrabenazine  and  lamotrigine  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "119",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Lamotrigine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021490",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021490_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"tetrabenazine\" outputclass=\"int-heading-drug\">tetrabenazine</ph> and <ph otherprops=\"lapatinib\" outputclass=\"int-drug\">lapatinib</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  tetrabenazine  and  lapatinib  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						}
					],
					"hasOrder": "120",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Lapatinib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021491",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021491_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"tetrabenazine\" outputclass=\"int-heading-drug\">tetrabenazine</ph> and <ph otherprops=\"lenvatinib\" outputclass=\"int-drug\">lenvatinib</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  tetrabenazine  and  lenvatinib  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						}
					],
					"hasOrder": "121",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Lenvatinib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021492",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021492_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tetrabenazine\" outputclass=\"int-heading-drug\">tetrabenazine</ph> and <ph otherprops=\"levetiracetam\" outputclass=\"int-drug\">levetiracetam</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tetrabenazine  and  levetiracetam  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "122",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Levetiracetam</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021493",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021493_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"tetrabenazine\" outputclass=\"int-heading-drug\">Tetrabenazine</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">decrease</ph> <ph outputclass=\"int-parameter\">the effects of</ph> <ph otherprops=\"levodopa\" outputclass=\"int-drug\">levodopa</ph>. <ph outputclass=\"int-action\">Manufacturer advises use with caution or avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Tetrabenazine   is predicted to   decrease   the effects of   levodopa .  Manufacturer advises use with caution or avoid .    \n\n"
						}
					],
					"hasOrder": "123",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Levodopa</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021494",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021494_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"tetrabenazine\" outputclass=\"int-heading-drug\">tetrabenazine</ph> and <ph otherprops=\"levomepromazine\" outputclass=\"int-drug\">levomepromazine</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  tetrabenazine  and  levomepromazine  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021494_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tetrabenazine\" outputclass=\"int-heading-drug\">tetrabenazine</ph> and <ph otherprops=\"levomepromazine\" outputclass=\"int-drug\">levomepromazine</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "2",
							"hasTextContent": "Both  tetrabenazine  and  levomepromazine  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "124",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Levomepromazine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021495",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021495_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tetrabenazine\" outputclass=\"int-heading-drug\">tetrabenazine</ph> and <ph otherprops=\"lidocaine\" outputclass=\"int-drug\">lidocaine</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tetrabenazine  and  lidocaine  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "125",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Lidocaine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021496",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021496_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"tetrabenazine\" outputclass=\"int-heading-drug\">tetrabenazine</ph> and <ph otherprops=\"lithium\" outputclass=\"int-drug\">lithium</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  tetrabenazine  and  lithium  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						}
					],
					"hasOrder": "126",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Lithium</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021497",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021497_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tetrabenazine\" outputclass=\"int-heading-drug\">tetrabenazine</ph> and <ph otherprops=\"lofepramine\" outputclass=\"int-drug\">lofepramine</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tetrabenazine  and  lofepramine  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "127",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Lofepramine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021498",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021498_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"tetrabenazine\" outputclass=\"int-heading-drug\">tetrabenazine</ph> and <ph otherprops=\"lofexidine\" outputclass=\"int-drug\">lofexidine</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  tetrabenazine  and  lofexidine  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021498_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tetrabenazine\" outputclass=\"int-heading-drug\">tetrabenazine</ph> and <ph otherprops=\"lofexidine\" outputclass=\"int-drug\">lofexidine</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "2",
							"hasTextContent": "Both  tetrabenazine  and  lofexidine  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "128",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Lofexidine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021499",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021499_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tetrabenazine\" outputclass=\"int-heading-drug\">tetrabenazine</ph> and <ph otherprops=\"loprazolam\" outputclass=\"int-drug\">loprazolam</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tetrabenazine  and  loprazolam  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "129",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Loprazolam</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021500",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021500_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tetrabenazine\" outputclass=\"int-heading-drug\">tetrabenazine</ph> and <ph otherprops=\"lorazepam\" outputclass=\"int-drug\">lorazepam</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tetrabenazine  and  lorazepam  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "130",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Lorazepam</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021501",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021501_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tetrabenazine\" outputclass=\"int-heading-drug\">tetrabenazine</ph> and <ph otherprops=\"lormetazepam\" outputclass=\"int-drug\">lormetazepam</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tetrabenazine  and  lormetazepam  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "131",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Lormetazepam</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021502",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021502_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tetrabenazine\" outputclass=\"int-heading-drug\">tetrabenazine</ph> and <ph otherprops=\"loxapine\" outputclass=\"int-drug\">loxapine</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tetrabenazine  and  loxapine  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "132",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Loxapine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021503",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021503_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tetrabenazine\" outputclass=\"int-heading-drug\">tetrabenazine</ph> and <ph otherprops=\"lurasidone\" outputclass=\"int-drug\">lurasidone</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tetrabenazine  and  lurasidone  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "133",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Lurasidone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021504",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021504_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"mefloquine\" outputclass=\"int-drug\">Mefloquine</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of QT-prolongation when given with</ph> <ph otherprops=\"tetrabenazine\" outputclass=\"int-heading-drug\">tetrabenazine</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Mefloquine   is predicted to   increase   the risk of QT-prolongation when given with   tetrabenazine .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "134",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Mefloquine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021505",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021505_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tetrabenazine\" outputclass=\"int-heading-drug\">tetrabenazine</ph> and <ph otherprops=\"melatonin\" outputclass=\"int-drug\">melatonin</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tetrabenazine  and  melatonin  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "135",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Melatonin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021506",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021506_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tetrabenazine\" outputclass=\"int-heading-drug\">tetrabenazine</ph> and <ph otherprops=\"mepivacaine\" outputclass=\"int-drug\">mepivacaine</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tetrabenazine  and  mepivacaine  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "136",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Mepivacaine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021507",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021507_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tetrabenazine\" outputclass=\"int-heading-drug\">tetrabenazine</ph> and <ph otherprops=\"meptazinol\" outputclass=\"int-drug\">meptazinol</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tetrabenazine  and  meptazinol  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "137",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Meptazinol</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021508",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021508_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"tetrabenazine\" outputclass=\"int-heading-drug\">tetrabenazine</ph> and <ph otherprops=\"methadone\" outputclass=\"int-drug\">methadone</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  tetrabenazine  and  methadone  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021508_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tetrabenazine\" outputclass=\"int-heading-drug\">tetrabenazine</ph> and <ph otherprops=\"methadone\" outputclass=\"int-drug\">methadone</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "2",
							"hasTextContent": "Both  tetrabenazine  and  methadone  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "138",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Methadone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021509",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021509_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tetrabenazine\" outputclass=\"int-heading-drug\">tetrabenazine</ph> and <ph otherprops=\"methocarbamol\" outputclass=\"int-drug\">methocarbamol</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tetrabenazine  and  methocarbamol  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "139",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Methocarbamol</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021510",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021510_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tetrabenazine\" outputclass=\"int-heading-drug\">tetrabenazine</ph> and <ph otherprops=\"methoxyflurane\" outputclass=\"int-drug\">methoxyflurane</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tetrabenazine  and  methoxyflurane  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "140",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Methoxyflurane</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021511",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021511_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"methylprednisolone\" outputclass=\"int-drug\">Methylprednisolone</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">cause</ph> <ph outputclass=\"int-parameter\">hypokalaemia (potentially increasing the risk of torsade de pointes) when given with</ph> <ph otherprops=\"tetrabenazine\" outputclass=\"int-heading-drug\">tetrabenazine</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Methylprednisolone   is predicted to   cause   hypokalaemia (potentially increasing the risk of torsade de pointes) when given with   tetrabenazine .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "141",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Methylprednisolone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021512",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021512_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"metolazone\" outputclass=\"int-drug\">Metolazone</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">cause</ph> <ph outputclass=\"int-parameter\">hypokalaemia (potentially increasing the risk of torsade de pointes) when given with</ph> <ph otherprops=\"tetrabenazine\" outputclass=\"int-heading-drug\">tetrabenazine</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Metolazone   is predicted to   cause   hypokalaemia (potentially increasing the risk of torsade de pointes) when given with   tetrabenazine .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "142",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Metolazone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021513",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021513_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tetrabenazine\" outputclass=\"int-heading-drug\">tetrabenazine</ph> and <ph otherprops=\"mianserin\" outputclass=\"int-drug\">mianserin</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tetrabenazine  and  mianserin  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "143",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Mianserin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021514",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021514_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tetrabenazine\" outputclass=\"int-heading-drug\">tetrabenazine</ph> and <ph otherprops=\"midazolam\" outputclass=\"int-drug\">midazolam</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tetrabenazine  and  midazolam  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "144",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Midazolam</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021515",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021515_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tetrabenazine\" outputclass=\"int-heading-drug\">tetrabenazine</ph> and <ph otherprops=\"mirtazapine\" outputclass=\"int-drug\">mirtazapine</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tetrabenazine  and  mirtazapine  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "145",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Mirtazapine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021516",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021516_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"mizolastine\" outputclass=\"int-drug\">Mizolastine</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of QT-prolongation when given with</ph> <ph otherprops=\"tetrabenazine\" outputclass=\"int-heading-drug\">tetrabenazine</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Mizolastine   is predicted to   increase   the risk of QT-prolongation when given with   tetrabenazine .  Manufacturer advises avoid .    \n\n"
						}
					],
					"hasOrder": "146",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Mizolastine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021517",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021517_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"tetrabenazine\" outputclass=\"int-heading-drug\">Tetrabenazine</ph> <ph outputclass=\"int-effectQualifier\">potentially</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the risk of CNS excitation and hypertension when given with</ph> <ph otherprops=\"moclobemide\" outputclass=\"int-drug\">moclobemide</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Tetrabenazine   potentially   increases   the risk of CNS excitation and hypertension when given with   moclobemide .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "147",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Moclobemide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021518",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021518_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tetrabenazine\" outputclass=\"int-heading-drug\">tetrabenazine</ph> and <ph otherprops=\"morphine\" outputclass=\"int-drug\">morphine</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tetrabenazine  and  morphine  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "148",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Morphine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021519",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021519_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"tetrabenazine\" outputclass=\"int-heading-drug\">tetrabenazine</ph> and <ph otherprops=\"moxifloxacin\" outputclass=\"int-drug\">moxifloxacin</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  tetrabenazine  and  moxifloxacin  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						}
					],
					"hasOrder": "149",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Moxifloxacin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021520",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021520_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tetrabenazine\" outputclass=\"int-heading-drug\">tetrabenazine</ph> and <ph otherprops=\"moxonidine\" outputclass=\"int-drug\">moxonidine</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tetrabenazine  and  moxonidine  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "150",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Moxonidine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021521",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021521_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tetrabenazine\" outputclass=\"int-heading-drug\">tetrabenazine</ph> and <ph otherprops=\"nabilone\" outputclass=\"int-drug\">nabilone</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tetrabenazine  and  nabilone  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "151",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Nabilone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021522",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021522_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"tetrabenazine\" outputclass=\"int-heading-drug\">tetrabenazine</ph> and <ph otherprops=\"nilotinib\" outputclass=\"int-drug\">nilotinib</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  tetrabenazine  and  nilotinib  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						}
					],
					"hasOrder": "152",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Nilotinib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021523",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021523_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tetrabenazine\" outputclass=\"int-heading-drug\">tetrabenazine</ph> and <ph otherprops=\"nitrazepam\" outputclass=\"int-drug\">nitrazepam</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tetrabenazine  and  nitrazepam  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "153",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Nitrazepam</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021524",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021524_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tetrabenazine\" outputclass=\"int-heading-drug\">tetrabenazine</ph> and <ph otherprops=\"nitrous oxide\" outputclass=\"int-drug\">nitrous oxide</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tetrabenazine  and  nitrous oxide  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "154",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Nitrous oxide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021525",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021525_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tetrabenazine\" outputclass=\"int-heading-drug\">tetrabenazine</ph> and <ph otherprops=\"nortriptyline\" outputclass=\"int-drug\">nortriptyline</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tetrabenazine  and  nortriptyline  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "155",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Nortriptyline</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021526",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021526_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tetrabenazine\" outputclass=\"int-heading-drug\">tetrabenazine</ph> and <ph otherprops=\"olanzapine\" outputclass=\"int-drug\">olanzapine</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tetrabenazine  and  olanzapine  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "156",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Olanzapine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021527",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021527_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"olodaterol\" outputclass=\"int-drug\">Olodaterol</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">cause</ph> <ph outputclass=\"int-parameter\">hypokalaemia (potentially increasing the risk of torsade de pointes) when given with</ph> <ph otherprops=\"tetrabenazine\" outputclass=\"int-heading-drug\">tetrabenazine</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Olodaterol   is predicted to   cause   hypokalaemia (potentially increasing the risk of torsade de pointes) when given with   tetrabenazine .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "157",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Olodaterol</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021528",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021528_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"tetrabenazine\" outputclass=\"int-heading-drug\">tetrabenazine</ph> and <ph otherprops=\"ondansetron\" outputclass=\"int-drug\">ondansetron</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  tetrabenazine  and  ondansetron  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						}
					],
					"hasOrder": "158",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Ondansetron</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021529",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021529_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"tetrabenazine\" outputclass=\"int-heading-drug\">tetrabenazine</ph> and <ph otherprops=\"osilodrostat\" outputclass=\"int-drug\">osilodrostat</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  tetrabenazine  and  osilodrostat  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						}
					],
					"hasOrder": "159",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Osilodrostat</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021530",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021530_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"tetrabenazine\" outputclass=\"int-heading-drug\">tetrabenazine</ph> and <ph otherprops=\"osimertinib\" outputclass=\"int-drug\">osimertinib</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  tetrabenazine  and  osimertinib  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						}
					],
					"hasOrder": "160",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Osimertinib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021531",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021531_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tetrabenazine\" outputclass=\"int-heading-drug\">tetrabenazine</ph> and <ph otherprops=\"oxazepam\" outputclass=\"int-drug\">oxazepam</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tetrabenazine  and  oxazepam  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "161",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Oxazepam</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021532",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021532_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tetrabenazine\" outputclass=\"int-heading-drug\">tetrabenazine</ph> and <ph otherprops=\"oxycodone\" outputclass=\"int-drug\">oxycodone</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tetrabenazine  and  oxycodone  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "162",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Oxycodone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021533",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021533_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"ozanimod\" outputclass=\"int-drug\">Ozanimod</ph> <ph outputclass=\"int-effectQualifier\">might</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of QT-prolongation when given with</ph> <ph otherprops=\"tetrabenazine\" outputclass=\"int-heading-drug\">tetrabenazine</ph>. <ph outputclass=\"int-action\">Manufacturer advises caution</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Ozanimod   might   increase   the risk of QT-prolongation when given with   tetrabenazine .  Manufacturer advises caution .    \n\n"
						}
					],
					"hasOrder": "163",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Ozanimod</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021534",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021534_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"tetrabenazine\" outputclass=\"int-heading-drug\">tetrabenazine</ph> and <ph otherprops=\"paliperidone\" outputclass=\"int-drug\">paliperidone</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  tetrabenazine  and  paliperidone  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021534_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tetrabenazine\" outputclass=\"int-heading-drug\">tetrabenazine</ph> and <ph otherprops=\"paliperidone\" outputclass=\"int-drug\">paliperidone</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "2",
							"hasTextContent": "Both  tetrabenazine  and  paliperidone  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "164",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Paliperidone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021535",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021535_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"palonosetron\" outputclass=\"int-drug\">Palonosetron</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of QT-prolongation when given with</ph> <ph otherprops=\"tetrabenazine\" outputclass=\"int-heading-drug\">tetrabenazine</ph>. <ph outputclass=\"int-action\">Manufacturer advises caution</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Palonosetron   is predicted to   increase   the risk of QT-prolongation when given with   tetrabenazine .  Manufacturer advises caution .    \n\n"
						}
					],
					"hasOrder": "165",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Palonosetron</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021536",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021536_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"tetrabenazine\" outputclass=\"int-heading-drug\">tetrabenazine</ph> and <ph otherprops=\"panobinostat\" outputclass=\"int-drug\">panobinostat</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  tetrabenazine  and  panobinostat  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						}
					],
					"hasOrder": "166",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Panobinostat</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021537",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021537_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"paroxetine\" outputclass=\"int-drug\">Paroxetine</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to the active metabolite of</ph> <ph otherprops=\"tetrabenazine\" outputclass=\"int-heading-drug\">tetrabenazine</ph>. <ph outputclass=\"int-action\">Manufacturer advises caution</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Paroxetine   is predicted to   increase   the exposure to the active metabolite of   tetrabenazine .  Manufacturer advises caution .    \n\n"
						}
					],
					"hasOrder": "167",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Paroxetine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021538",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021538_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"tetrabenazine\" outputclass=\"int-heading-drug\">tetrabenazine</ph> and <ph otherprops=\"pasireotide\" outputclass=\"int-drug\">pasireotide</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  tetrabenazine  and  pasireotide  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						}
					],
					"hasOrder": "168",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Pasireotide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021539",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021539_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"tetrabenazine\" outputclass=\"int-heading-drug\">tetrabenazine</ph> and <ph otherprops=\"pazopanib\" outputclass=\"int-drug\">pazopanib</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  tetrabenazine  and  pazopanib  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						}
					],
					"hasOrder": "169",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Pazopanib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021540",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021540_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph outputclass=\"int-route\">Intravenous</ph> <ph otherprops=\"pentamidine\" outputclass=\"int-drug\">pentamidine</ph> <ph outputclass=\"int-effectQualifier\">potentially</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the risk of QT-prolongation when given with</ph> <ph otherprops=\"tetrabenazine\" outputclass=\"int-heading-drug\">tetrabenazine</ph>. <ph outputclass=\"int-action\">Manufacturer advises caution</ph>.  </p>"
							},
							"hasEvidence": "Anecdotal",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Intravenous   pentamidine   potentially   increases   the risk of QT-prolongation when given with   tetrabenazine .  Manufacturer advises caution .    \n\n"
						}
					],
					"hasOrder": "170",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Pentamidine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021541",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021541_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tetrabenazine\" outputclass=\"int-heading-drug\">tetrabenazine</ph> and <ph otherprops=\"pentazocine\" outputclass=\"int-drug\">pentazocine</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tetrabenazine  and  pentazocine  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "171",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Pentazocine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021542",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021542_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tetrabenazine\" outputclass=\"int-heading-drug\">tetrabenazine</ph> and <ph otherprops=\"perampanel\" outputclass=\"int-drug\">perampanel</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tetrabenazine  and  perampanel  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "172",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Perampanel</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021543",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021543_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tetrabenazine\" outputclass=\"int-heading-drug\">tetrabenazine</ph> and <ph otherprops=\"pericyazine\" outputclass=\"int-drug\">pericyazine</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tetrabenazine  and  pericyazine  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "173",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Pericyazine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021544",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021544_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tetrabenazine\" outputclass=\"int-heading-drug\">tetrabenazine</ph> and <ph otherprops=\"pethidine\" outputclass=\"int-drug\">pethidine</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tetrabenazine  and  pethidine  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "174",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Pethidine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021545",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021545_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"tetrabenazine\" outputclass=\"int-heading-drug\">Tetrabenazine</ph> <ph outputclass=\"int-effectQualifier\">potentially</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the risk of CNS excitation and hypertension when given with</ph> <ph otherprops=\"phenelzine\" outputclass=\"int-drug\">phenelzine</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid and for 14 days after stopping the MAOI</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Tetrabenazine   potentially   increases   the risk of CNS excitation and hypertension when given with   phenelzine .  Manufacturer advises avoid and for 14 days after stopping the MAOI .    \n\n"
						}
					],
					"hasOrder": "175",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Phenelzine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021546",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021546_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tetrabenazine\" outputclass=\"int-heading-drug\">tetrabenazine</ph> and <ph otherprops=\"phenobarbital\" outputclass=\"int-drug\">phenobarbital</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tetrabenazine  and  phenobarbital  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "176",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Phenobarbital</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021547",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021547_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"tetrabenazine\" outputclass=\"int-heading-drug\">tetrabenazine</ph> and <ph otherprops=\"pimozide\" outputclass=\"int-drug\">pimozide</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  tetrabenazine  and  pimozide  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021547_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tetrabenazine\" outputclass=\"int-heading-drug\">tetrabenazine</ph> and <ph otherprops=\"pimozide\" outputclass=\"int-drug\">pimozide</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "2",
							"hasTextContent": "Both  tetrabenazine  and  pimozide  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "177",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Pimozide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021548",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021548_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tetrabenazine\" outputclass=\"int-heading-drug\">tetrabenazine</ph> and <ph otherprops=\"pizotifen\" outputclass=\"int-drug\">pizotifen</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tetrabenazine  and  pizotifen  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "178",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Pizotifen</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021549",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021549_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"ponesimod\" outputclass=\"int-drug\">Ponesimod</ph> <ph outputclass=\"int-effectQualifier\">might</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of QT-prolongation when given with</ph> <ph otherprops=\"tetrabenazine\" outputclass=\"int-heading-drug\">tetrabenazine</ph>. <ph outputclass=\"int-action\">Manufacturer advises caution</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Ponesimod   might   increase   the risk of QT-prolongation when given with   tetrabenazine .  Manufacturer advises caution .    \n\n"
						}
					],
					"hasOrder": "179",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Ponesimod</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021550",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021550_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"prednisolone\" outputclass=\"int-drug\">Prednisolone</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">cause</ph> <ph outputclass=\"int-parameter\">hypokalaemia (potentially increasing the risk of torsade de pointes) when given with</ph> <ph otherprops=\"tetrabenazine\" outputclass=\"int-heading-drug\">tetrabenazine</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Prednisolone   is predicted to   cause   hypokalaemia (potentially increasing the risk of torsade de pointes) when given with   tetrabenazine .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "180",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Prednisolone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021551",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021551_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tetrabenazine\" outputclass=\"int-heading-drug\">tetrabenazine</ph> and <ph otherprops=\"pregabalin\" outputclass=\"int-drug\">pregabalin</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tetrabenazine  and  pregabalin  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "181",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Pregabalin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021552",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021552_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tetrabenazine\" outputclass=\"int-heading-drug\">tetrabenazine</ph> and <ph otherprops=\"prilocaine\" outputclass=\"int-drug\">prilocaine</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tetrabenazine  and  prilocaine  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "182",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Prilocaine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021553",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021553_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tetrabenazine\" outputclass=\"int-heading-drug\">tetrabenazine</ph> and <ph otherprops=\"primidone\" outputclass=\"int-drug\">primidone</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tetrabenazine  and  primidone  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "183",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Primidone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021554",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021554_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tetrabenazine\" outputclass=\"int-heading-drug\">tetrabenazine</ph> and <ph otherprops=\"prochlorperazine\" outputclass=\"int-drug\">prochlorperazine</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tetrabenazine  and  prochlorperazine  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "184",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Prochlorperazine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021555",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021555_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tetrabenazine\" outputclass=\"int-heading-drug\">tetrabenazine</ph> and <ph otherprops=\"promazine\" outputclass=\"int-drug\">promazine</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tetrabenazine  and  promazine  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "185",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Promazine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021556",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021556_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tetrabenazine\" outputclass=\"int-heading-drug\">tetrabenazine</ph> and <ph otherprops=\"promethazine\" outputclass=\"int-drug\">promethazine</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tetrabenazine  and  promethazine  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "186",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Promethazine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021557",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021557_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tetrabenazine\" outputclass=\"int-heading-drug\">tetrabenazine</ph> and <ph otherprops=\"propofol\" outputclass=\"int-drug\">propofol</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tetrabenazine  and  propofol  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "187",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Propofol</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021558",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021558_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tetrabenazine\" outputclass=\"int-heading-drug\">tetrabenazine</ph> and <ph otherprops=\"quetiapine\" outputclass=\"int-drug\">quetiapine</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tetrabenazine  and  quetiapine  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "188",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Quetiapine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021559",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021559_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"tetrabenazine\" outputclass=\"int-heading-drug\">tetrabenazine</ph> and <ph otherprops=\"quinine\" outputclass=\"int-drug\">quinine</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  tetrabenazine  and  quinine  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						}
					],
					"hasOrder": "189",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Quinine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021560",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021560_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"tetrabenazine\" outputclass=\"int-heading-drug\">tetrabenazine</ph> and <ph otherprops=\"ranolazine\" outputclass=\"int-drug\">ranolazine</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  tetrabenazine  and  ranolazine  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						}
					],
					"hasOrder": "190",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Ranolazine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021561",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021561_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"tetrabenazine\" outputclass=\"int-heading-drug\">Tetrabenazine</ph> <ph outputclass=\"int-effectQualifier\">potentially</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the risk of CNS excitation and hypertension when given with</ph> <ph otherprops=\"rasagiline\" outputclass=\"int-drug\">rasagiline</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Tetrabenazine   potentially   increases   the risk of CNS excitation and hypertension when given with   rasagiline .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "191",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Rasagiline</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021562",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021562_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tetrabenazine\" outputclass=\"int-heading-drug\">tetrabenazine</ph> and <ph otherprops=\"remifentanil\" outputclass=\"int-drug\">remifentanil</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tetrabenazine  and  remifentanil  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "192",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Remifentanil</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021563",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021563_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tetrabenazine\" outputclass=\"int-heading-drug\">tetrabenazine</ph> and <ph otherprops=\"remimazolam\" outputclass=\"int-drug\">remimazolam</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tetrabenazine  and  remimazolam  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "193",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Remimazolam</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021564",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021564_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"tetrabenazine\" outputclass=\"int-heading-drug\">tetrabenazine</ph> and <ph otherprops=\"ribociclib\" outputclass=\"int-drug\">ribociclib</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  tetrabenazine  and  ribociclib  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						}
					],
					"hasOrder": "194",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Ribociclib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021565",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021565_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"tetrabenazine\" outputclass=\"int-heading-drug\">tetrabenazine</ph> and <ph otherprops=\"risperidone\" outputclass=\"int-drug\">risperidone</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  tetrabenazine  and  risperidone  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021565_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tetrabenazine\" outputclass=\"int-heading-drug\">tetrabenazine</ph> and <ph otherprops=\"risperidone\" outputclass=\"int-drug\">risperidone</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "2",
							"hasTextContent": "Both  tetrabenazine  and  risperidone  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "195",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Risperidone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021566",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021566_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tetrabenazine\" outputclass=\"int-heading-drug\">tetrabenazine</ph> and <ph otherprops=\"ropivacaine\" outputclass=\"int-drug\">ropivacaine</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tetrabenazine  and  ropivacaine  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "196",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Ropivacaine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021567",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021567_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"tetrabenazine\" outputclass=\"int-heading-drug\">Tetrabenazine</ph> <ph outputclass=\"int-effectQualifier\">potentially</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the risk of CNS excitation and hypertension when given with</ph> <ph otherprops=\"safinamide\" outputclass=\"int-drug\">safinamide</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Tetrabenazine   potentially   increases   the risk of CNS excitation and hypertension when given with   safinamide .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "197",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Safinamide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021568",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021568_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"salbutamol\" outputclass=\"int-drug\">Salbutamol</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">cause</ph> <ph outputclass=\"int-parameter\">hypokalaemia (potentially increasing the risk of torsade de pointes) when given with</ph> <ph otherprops=\"tetrabenazine\" outputclass=\"int-heading-drug\">tetrabenazine</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Salbutamol   is predicted to   cause   hypokalaemia (potentially increasing the risk of torsade de pointes) when given with   tetrabenazine .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "198",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Salbutamol</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021569",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021569_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"salmeterol\" outputclass=\"int-drug\">Salmeterol</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">cause</ph> <ph outputclass=\"int-parameter\">hypokalaemia (potentially increasing the risk of torsade de pointes) when given with</ph> <ph otherprops=\"tetrabenazine\" outputclass=\"int-heading-drug\">tetrabenazine</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Salmeterol   is predicted to   cause   hypokalaemia (potentially increasing the risk of torsade de pointes) when given with   tetrabenazine .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "199",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Salmeterol</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021570",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021570_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"tetrabenazine\" outputclass=\"int-heading-drug\">Tetrabenazine</ph> <ph outputclass=\"int-effectQualifier\">potentially</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the risk of CNS excitation and hypertension when given with</ph> <ph otherprops=\"selegiline\" outputclass=\"int-drug\">selegiline</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Tetrabenazine   potentially   increases   the risk of CNS excitation and hypertension when given with   selegiline .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "200",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Selegiline</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021571",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021571_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"tetrabenazine\" outputclass=\"int-heading-drug\">tetrabenazine</ph> and <ph otherprops=\"selpercatinib\" outputclass=\"int-drug\">selpercatinib</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  tetrabenazine  and  selpercatinib  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						}
					],
					"hasOrder": "201",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Selpercatinib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021572",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021572_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"tetrabenazine\" outputclass=\"int-heading-drug\">tetrabenazine</ph> and <ph otherprops=\"sevoflurane\" outputclass=\"int-drug\">sevoflurane</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  tetrabenazine  and  sevoflurane  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021572_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tetrabenazine\" outputclass=\"int-heading-drug\">tetrabenazine</ph> and <ph otherprops=\"sevoflurane\" outputclass=\"int-drug\">sevoflurane</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "2",
							"hasTextContent": "Both  tetrabenazine  and  sevoflurane  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "202",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Sevoflurane</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021573",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021573_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"tetrabenazine\" outputclass=\"int-heading-drug\">tetrabenazine</ph> and <ph otherprops=\"sildenafil\" outputclass=\"int-drug\">sildenafil</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  tetrabenazine  and  sildenafil  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						}
					],
					"hasOrder": "203",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Sildenafil</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021574",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021574_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"siponimod\" outputclass=\"int-drug\">Siponimod</ph> <ph outputclass=\"int-effectQualifier\">might</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of QT-prolongation when given with</ph> <ph otherprops=\"tetrabenazine\" outputclass=\"int-heading-drug\">tetrabenazine</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Siponimod   might   increase   the risk of QT-prolongation when given with   tetrabenazine .  Manufacturer advises avoid .    \n\n"
						}
					],
					"hasOrder": "204",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Siponimod</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021575",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021575_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tetrabenazine\" outputclass=\"int-heading-drug\">tetrabenazine</ph> and <ph otherprops=\"sodium oxybate\" outputclass=\"int-drug\">sodium oxybate</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tetrabenazine  and  sodium oxybate  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "205",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Sodium oxybate</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021576",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021576_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"tetrabenazine\" outputclass=\"int-heading-drug\">tetrabenazine</ph> and <ph otherprops=\"sorafenib\" outputclass=\"int-drug\">sorafenib</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  tetrabenazine  and  sorafenib  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						}
					],
					"hasOrder": "206",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Sorafenib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021577",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021577_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"tetrabenazine\" outputclass=\"int-heading-drug\">tetrabenazine</ph> and <ph otherprops=\"sotalol\" outputclass=\"int-drug\">sotalol</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  tetrabenazine  and  sotalol  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						}
					],
					"hasOrder": "207",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Sotalol</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021578",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021578_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"tetrabenazine\" outputclass=\"int-heading-drug\">tetrabenazine</ph> and <ph otherprops=\"sulpiride\" outputclass=\"int-drug\">sulpiride</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  tetrabenazine  and  sulpiride  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021578_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tetrabenazine\" outputclass=\"int-heading-drug\">tetrabenazine</ph> and <ph otherprops=\"sulpiride\" outputclass=\"int-drug\">sulpiride</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "2",
							"hasTextContent": "Both  tetrabenazine  and  sulpiride  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "208",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Sulpiride</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021579",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021579_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"tetrabenazine\" outputclass=\"int-heading-drug\">tetrabenazine</ph> and <ph otherprops=\"sunitinib\" outputclass=\"int-drug\">sunitinib</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  tetrabenazine  and  sunitinib  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						}
					],
					"hasOrder": "209",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Sunitinib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021580",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021580_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tetrabenazine\" outputclass=\"int-heading-drug\">tetrabenazine</ph> and <ph otherprops=\"tapentadol\" outputclass=\"int-drug\">tapentadol</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tetrabenazine  and  tapentadol  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "210",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Tapentadol</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021581",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021581_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tetrabenazine\" outputclass=\"int-heading-drug\">tetrabenazine</ph> and <ph otherprops=\"temazepam\" outputclass=\"int-drug\">temazepam</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tetrabenazine  and  temazepam  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "211",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Temazepam</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021582",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021582_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"terbinafine\" outputclass=\"int-drug\">Terbinafine</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to the active metabolite of</ph> <ph otherprops=\"tetrabenazine\" outputclass=\"int-heading-drug\">tetrabenazine</ph>. <ph outputclass=\"int-action\">Manufacturer advises caution</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Terbinafine   is predicted to   increase   the exposure to the active metabolite of   tetrabenazine .  Manufacturer advises caution .    \n\n"
						}
					],
					"hasOrder": "212",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Terbinafine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021583",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021583_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"terbutaline\" outputclass=\"int-drug\">Terbutaline</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">cause</ph> <ph outputclass=\"int-parameter\">hypokalaemia (potentially increasing the risk of torsade de pointes) when given with</ph> <ph otherprops=\"tetrabenazine\" outputclass=\"int-heading-drug\">tetrabenazine</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Terbutaline   is predicted to   cause   hypokalaemia (potentially increasing the risk of torsade de pointes) when given with   tetrabenazine .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "213",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Terbutaline</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021584",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021584_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tetrabenazine\" outputclass=\"int-heading-drug\">tetrabenazine</ph> and <ph otherprops=\"tetracaine\" outputclass=\"int-drug\">tetracaine</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tetrabenazine  and  tetracaine  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "214",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Tetracaine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021585",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021585_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tetrabenazine\" outputclass=\"int-heading-drug\">tetrabenazine</ph> and <ph otherprops=\"thalidomide\" outputclass=\"int-drug\">thalidomide</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tetrabenazine  and  thalidomide  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "215",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Thalidomide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021586",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021586_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"theophylline\" outputclass=\"int-drug\">Theophylline</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">cause</ph> <ph outputclass=\"int-parameter\">hypokalaemia (potentially increasing the risk of torsade de pointes) when given with</ph> <ph otherprops=\"tetrabenazine\" outputclass=\"int-heading-drug\">tetrabenazine</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Theophylline   is predicted to   cause   hypokalaemia (potentially increasing the risk of torsade de pointes) when given with   tetrabenazine .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "216",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Theophylline</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021587",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021587_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tetrabenazine\" outputclass=\"int-heading-drug\">tetrabenazine</ph> and <ph otherprops=\"thiopental\" outputclass=\"int-drug\">thiopental</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tetrabenazine  and  thiopental  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "217",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Thiopental</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021588",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021588_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"tetrabenazine\" outputclass=\"int-heading-drug\">tetrabenazine</ph> and <ph otherprops=\"tizanidine\" outputclass=\"int-drug\">tizanidine</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  tetrabenazine  and  tizanidine  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021588_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tetrabenazine\" outputclass=\"int-heading-drug\">tetrabenazine</ph> and <ph otherprops=\"tizanidine\" outputclass=\"int-drug\">tizanidine</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "2",
							"hasTextContent": "Both  tetrabenazine  and  tizanidine  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "218",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Tizanidine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021589",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021589_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"tetrabenazine\" outputclass=\"int-heading-drug\">tetrabenazine</ph> and <ph otherprops=\"tolterodine\" outputclass=\"int-drug\">tolterodine</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  tetrabenazine  and  tolterodine  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						}
					],
					"hasOrder": "219",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Tolterodine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021590",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021590_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"torasemide\" outputclass=\"int-drug\">Torasemide</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">cause</ph> <ph outputclass=\"int-parameter\">hypokalaemia (potentially increasing the risk of torsade de pointes) when given with</ph> <ph otherprops=\"tetrabenazine\" outputclass=\"int-heading-drug\">tetrabenazine</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Torasemide   is predicted to   cause   hypokalaemia (potentially increasing the risk of torsade de pointes) when given with   tetrabenazine .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "220",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Torasemide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021591",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021591_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"tetrabenazine\" outputclass=\"int-heading-drug\">tetrabenazine</ph> and <ph otherprops=\"toremifene\" outputclass=\"int-drug\">toremifene</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  tetrabenazine  and  toremifene  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						}
					],
					"hasOrder": "221",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Toremifene</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021592",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021592_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tetrabenazine\" outputclass=\"int-heading-drug\">tetrabenazine</ph> and <ph otherprops=\"tramadol\" outputclass=\"int-drug\">tramadol</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tetrabenazine  and  tramadol  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "222",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Tramadol</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021593",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021593_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"tetrabenazine\" outputclass=\"int-heading-drug\">Tetrabenazine</ph> <ph outputclass=\"int-effectQualifier\">potentially</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the risk of CNS excitation and hypertension when given with</ph> <ph otherprops=\"tranylcypromine\" outputclass=\"int-drug\">tranylcypromine</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid and for 14 days after stopping the MAOI</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Tetrabenazine   potentially   increases   the risk of CNS excitation and hypertension when given with   tranylcypromine .  Manufacturer advises avoid and for 14 days after stopping the MAOI .    \n\n"
						}
					],
					"hasOrder": "223",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Tranylcypromine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021594",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021594_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tetrabenazine\" outputclass=\"int-heading-drug\">tetrabenazine</ph> and <ph otherprops=\"trazodone\" outputclass=\"int-drug\">trazodone</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tetrabenazine  and  trazodone  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "224",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Trazodone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021595",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021595_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"triamcinolone\" outputclass=\"int-drug\">Triamcinolone</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">cause</ph> <ph outputclass=\"int-parameter\">hypokalaemia (potentially increasing the risk of torsade de pointes) when given with</ph> <ph otherprops=\"tetrabenazine\" outputclass=\"int-heading-drug\">tetrabenazine</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Triamcinolone   is predicted to   cause   hypokalaemia (potentially increasing the risk of torsade de pointes) when given with   tetrabenazine .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "225",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Triamcinolone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021596",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021596_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tetrabenazine\" outputclass=\"int-heading-drug\">tetrabenazine</ph> and <ph otherprops=\"trifluoperazine\" outputclass=\"int-drug\">trifluoperazine</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tetrabenazine  and  trifluoperazine  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "226",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Trifluoperazine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021597",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021597_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tetrabenazine\" outputclass=\"int-heading-drug\">tetrabenazine</ph> and <ph otherprops=\"trimipramine\" outputclass=\"int-drug\">trimipramine</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tetrabenazine  and  trimipramine  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "227",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Trimipramine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021598",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021598_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"tetrabenazine\" outputclass=\"int-heading-drug\">tetrabenazine</ph> and <ph otherprops=\"vandetanib\" outputclass=\"int-drug\">vandetanib</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  tetrabenazine  and  vandetanib  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						}
					],
					"hasOrder": "228",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Vandetanib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021599",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021599_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"tetrabenazine\" outputclass=\"int-heading-drug\">tetrabenazine</ph> and <ph otherprops=\"vardenafil\" outputclass=\"int-drug\">vardenafil</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  tetrabenazine  and  vardenafil  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						}
					],
					"hasOrder": "229",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Vardenafil</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021600",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021600_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"tetrabenazine\" outputclass=\"int-heading-drug\">tetrabenazine</ph> and <ph otherprops=\"vemurafenib\" outputclass=\"int-drug\">vemurafenib</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  tetrabenazine  and  vemurafenib  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						}
					],
					"hasOrder": "230",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Vemurafenib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021601",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021601_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"tetrabenazine\" outputclass=\"int-heading-drug\">tetrabenazine</ph> and <ph otherprops=\"venlafaxine\" outputclass=\"int-drug\">venlafaxine</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  tetrabenazine  and  venlafaxine  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021601_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tetrabenazine\" outputclass=\"int-heading-drug\">tetrabenazine</ph> and <ph otherprops=\"venlafaxine\" outputclass=\"int-drug\">venlafaxine</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "2",
							"hasTextContent": "Both  tetrabenazine  and  venlafaxine  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "231",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Venlafaxine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021602",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021602_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"tetrabenazine\" outputclass=\"int-heading-drug\">tetrabenazine</ph> and <ph otherprops=\"vernakalant\" outputclass=\"int-drug\">vernakalant</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  tetrabenazine  and  vernakalant  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						}
					],
					"hasOrder": "232",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Vernakalant</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021603",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021603_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"vilanterol\" outputclass=\"int-drug\">Vilanterol</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">cause</ph> <ph outputclass=\"int-parameter\">hypokalaemia (potentially increasing the risk of torsade de pointes) when given with</ph> <ph otherprops=\"tetrabenazine\" outputclass=\"int-heading-drug\">tetrabenazine</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Vilanterol   is predicted to   cause   hypokalaemia (potentially increasing the risk of torsade de pointes) when given with   tetrabenazine .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "233",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Vilanterol</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021604",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021604_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"tetrabenazine\" outputclass=\"int-heading-drug\">tetrabenazine</ph> and <ph otherprops=\"vinflunine\" outputclass=\"int-drug\">vinflunine</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  tetrabenazine  and  vinflunine  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						}
					],
					"hasOrder": "234",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Vinflunine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021605",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021605_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"tetrabenazine\" outputclass=\"int-heading-drug\">tetrabenazine</ph> and <ph otherprops=\"voriconazole\" outputclass=\"int-drug\">voriconazole</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  tetrabenazine  and  voriconazole  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						}
					],
					"hasOrder": "235",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Voriconazole</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021606",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021606_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"xipamide\" outputclass=\"int-drug\">Xipamide</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">cause</ph> <ph outputclass=\"int-parameter\">hypokalaemia (potentially increasing the risk of torsade de pointes) when given with</ph> <ph otherprops=\"tetrabenazine\" outputclass=\"int-heading-drug\">tetrabenazine</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Xipamide   is predicted to   cause   hypokalaemia (potentially increasing the risk of torsade de pointes) when given with   tetrabenazine .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "236",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Xipamide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021607",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021607_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tetrabenazine\" outputclass=\"int-heading-drug\">tetrabenazine</ph> and <ph otherprops=\"zolpidem\" outputclass=\"int-drug\">zolpidem</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tetrabenazine  and  zolpidem  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "237",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Zolpidem</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021608",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021608_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tetrabenazine\" outputclass=\"int-heading-drug\">tetrabenazine</ph> and <ph otherprops=\"zopiclone\" outputclass=\"int-drug\">zopiclone</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tetrabenazine  and  zopiclone  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "238",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Zopiclone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021609",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021609_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"tetrabenazine\" outputclass=\"int-heading-drug\">tetrabenazine</ph> and <ph otherprops=\"zuclopenthixol\" outputclass=\"int-drug\">zuclopenthixol</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  tetrabenazine  and  zuclopenthixol  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2#bnf_i1643858021609_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tetrabenazine\" outputclass=\"int-heading-drug\">tetrabenazine</ph> and <ph otherprops=\"zuclopenthixol\" outputclass=\"int-drug\">zuclopenthixol</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "2",
							"hasTextContent": "Both  tetrabenazine  and  zuclopenthixol  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "239",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Zuclopenthixol</title>"
					}
				}
			],
			"hasSearchLabel": " Tetrabenazine  | Interactions",
			"hasSearchLink": {
				"@id": "http://bnf.nice.org.uk/interaction/tetrabenazine-2.html"
			},
			"hasTitle": {
				"@type": "rdf:XMLLiteral",
				"@value": "<title> Tetrabenazine </title>"
			},
			"rdfs:label": "tetrabenazine"
		}
	]
}